An interim analysis of non-interventional study of the epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia

Cover Page

Cite item

Full Text

Abstract

Objective: to study the clinical and demographic profile of patients with non-metatstatic castration-resistant prostate cancer (nmCRPC) and clinical approaches to the treatment of nmCRPC in the context of daily medical practice before and after progression M1 stage.
Materials and methods. The multicenter non-interventional epidemiological study is planned to include 200 patients with a documented diagnosis of nmCRPC from 2019 to 2020. The interim report has included data on 108 patients from 13 centers located in different regions of the Russian Federation. The median age of the patients was 73 (55—90) years.
Results and conclusion. When the diagnosis of nmCRPC was made, the median prostate specific antigen was 8.23 (0.17—116.9) ng/ml, and the prostate specific antigen doubling time was 6 (1—50) months. When diagnosed nmCRPC, 86 patients (79.6 %) underwent a change of therapy, of which 42 % were prescribed modern regimens containing the new generation non-steroid antiandrogens (apalutamide, enzalutamide).

About the authors

B. Ya. Alekseev

National Medical Research Radiological Center, Ministry of Health of Russia; Medical Institute of Continuing Education, Moscow State University of Food Production

Author for correspondence.
Email: byalekseev@mail.ru
ORCID iD: 0000-0002-3398-4128
3 2nd Botkinskiy Proezd, Moscow 125284; 11 Volokolamskoe Shosse, Moscow 125080. Russian Federation

K. M. Nyushko

National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0002-4171-6211
3 2nd Botkinskiy Proezd, Moscow 125284. Russian Federation

R. A. Gafanov

Russian Scientific Center of Roentgen Radiology, Ministry of Health of Russia

ORCID iD: 0000-0002-7592-0392
86 Profsoyuznaya St., Moscow 117997. Russian Federation

A. A. Kirichek

Moscow City Oncological Hospital No. 62, Moscow Healthcare Department

ORCID iD: 0000-0002-3672-2369
27 Istra, Moscow region 143423. Russian Federation

Yu. V. Anzhiganova

A.I. Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary

ORCID iD: 0000-0002-8388-466X
16 1st Smolenskaya St., Krasnoyarsk 660133. Russian Federation

E. I. Kopyltsov

Clinical Oncology Dispensary

ORCID iD: 0000-0003-3165-9118
Build. 1, 9 Zavertyaeva St., Omsk 644013. Russian Federation

Yu. Yu. Sundui

City Clinical Cancer Hospital No. 1, Moscow Healthcare Department

ORCID iD: 0000-0003-1217-1491

17 / 1 Baumanskaya St., Moscow 105005.

Russian Federation

V. B. Matveev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0001-7748-9527
24 Kashirskoe Shosse, Moscow 115478. Russian Federation

References

  1. Malignant tumors in Russia in 2018 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMITS radiologii” Minzdrava Rossii, 2019. 250 p. (In Russ.).
  2. State of oncological care in Russia in 2018. Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMITS radiologii” Minzdrava Rossii, 2019. 236 p. (In Russ.).
  3. Clinical guideline by the Russian Association of Oncologists. Prostate cancer. 2019. Available at: https://oncology-association.ru/clinical-guidelines-kr (accessed: 13.12.2019). (In Russ.).
  4. Mottet N., Cornford P., van den Bergh R.C.N. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Eur Urol 2018. Available at: https://uroweb.org/guideline/prostate-cancer.
  5. Kirby M., Hirst C., Crawford E.D. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65(11):1180-92. doi: 10.1111/j.1742-1241.2011.02799.x.
  6. Li T.T., Shore N.D., Mehra M. et al. Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized disease. Cancer 2017;123(18):3591-601. doi: 10.1002/cncr.30784.
  7. Tombal B. Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient? Ann Oncol 2012;23 Suppl 10:x251-8. doi: 10.1093/annonc/mds325.
  8. Marteau F., Gimonet G., Gabriel S. et al. Epidemiology of patients with metastatic castrate resistant prostate cancer in Europe and Australia. Value Health 2014;17(7):A619. doi: 10.1016/j.jval.2014.08.2188.
  9. Liede A. International prevalence of nonmetastatic (M0) castration-resistant prostate cancer (CRPC). J Clin Oncol 2017;31(15_suppl).
  10. Howard L.E., Moreira D.M., De Hoedt A. et al. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int 2017;120(5B): E80-6. doi: 10.1111/bju.13856.
  11. Smith M.R., Cook R., Lee K.A., Nelson J.B. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 2011;117(10):2077-85. doi: 10.1002/cncr.25762.
  12. Smith M.R., Kabbinavar F., Saad F. et al. Natural history of rising serum prostatespecific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005;23(13):2918-25. doi: 10.1200/JCO.2005.01.529.
  13. Scher H.I., Morris M.J., Stadler W.M. et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 2016;34(12):1402-18. doi: 10.1200/JCO.2015.64.2702.
  14. Virgo K., Basch E., Loblaw D.A. et al. Second-line hormonal therapy for men with chemotherapy-naive, castrationresistant prostate cancer: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 2017;35(17):1952-64. doi: 10.1200/JCO.2017.72.8030.
  15. Fendler W.P. Poster presentation at SUO 2018. Annotation No. 202. (In Russ.).
  16. Saad F., Chi K.N., Finelli A. et al. The 2015 CUA0CUOG guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J 2015;9(3-4):90-6. doi: 10.5489/cuaj.2526.
  17. American Cancer Society. Cancer Facts & Figures. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf. Accessed May 2020.
  18. Smith M.R., Saad F., Chowdhury S. et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018;378(15):1408-18. doi: 10.1056/NEJMoa1715546.
  19. Hussain M., Fizazi K., Saad F. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018;378(26):2465-74. doi: 10.1056/NEJMoa1800536.
  20. Small E., Saad F., Chowdhury S. et al. Final survival results from SPARTAN, a phase 3 study of apalutamide (APA) vs placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO 2020. Poster presentation (Abstract #5516).
  21. Recommendations on the treatment of prostate cancer. Available at: http://cr.rosminzdrav.ru/#!/recomend/99. (In Russ.).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.